Medical

FDA has confirmed HPPI's clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission PR...

Precision Therapeutics Receives Approval of Delisting Request from German Stock Exchange

162

MINNEAPOLIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial...

Progressive Care Reports $1.7 Million in Revenues in July

General

Progressive Care Earns Coveted LegitScript Certification Verifying PharmCo Pharmacy is a Safe and Credible Online Health Resource

158

MIAMI, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that...

Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies

165

ORLANDO, Fla., July 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the...

Research on Lodonal for HIV related GI complications featured in Plus Magazine

153

ORLANDO, Fla., July 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the...

Precision Therapeutics Merger with Helomics Corp. Accelerates Personalized Cancer Treatment Strategies

141

In an Interview with CEOCFO Magazine, CEO Dr. Carl Schwartz Explains how the Company's Database of Tumors, Artificial Intelligence Technology,...

Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System

131

MINNEAPOLIS , July 12, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial...

Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation

126

MINNEAPOLIS, June 28, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence...

First Choice Healthcare Completes $15.45 Million Sale and Leaseback of Marina Towers

Taglich Brothers Initiates Coverage of First Choice Healthcare Solutions, Inc.

by Anthony Ramsumiran

120

NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of First Choice Healthcare Solutions,...

CytoDyn Injects First Patient in Its Current Phase 3 Study

CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy

by Anthony Ramsumiran

126

Rolling BLA Submission Starting as Early as the End of 2018 - FDA Provides Guidance on Ongoing Requirements VANCOUVER, Washington,...

Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study

by Anthony Ramsumiran

117

FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel...

Finance

BioCorRx Raises $1.1 Million at Premium to Market

128

ANAHEIM, CA, June 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions...

Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States

127

ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune," “IMUN” or...

Innovus Pharmaceuticals Announces the Closing of the Acquisition of All of Beyond Human, LLCs Products Which Generated Over $2.2 Million in Sales in 2015

Innovus Pharma Announces the Approval of its Product ProstaGorx in Canada for Benign Prostate Hyperplasia (“BPH”)

116

ProstaGorx is the Ninth Innovus Pharma Product Approved in Canada to Date SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) --...

Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9

120

VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial...

Precision Therapeutics to Hold Business Update Conference Call on May 15, 2018

Precision Therapeutics Launches New Website

116

MINNEAPOLIS, May 31, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence...

Co-Diagnostics, Inc. Announces Joint Venture in India

Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

116

CoPrimers™ used in proof of concept evaluation SALT LAKE CITY--(BUSINESS WIRE)-- Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique,...

NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

135

Median survival of top 100 patients is 40.5 months,Median survival of all 331 patients is 23.1 months, Longest survivors have...

LexaGene Enters Collaboration to Incorporate Cancer Sequencing Technology into a New Product

121

BEVERLY, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for...

Video News on Precision Therapeutics Inc (Nasdaq: AIPT) – Company Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018